1 |
Mastroianni A, Greco S, Chidichimo L, Mauro MV, Urso F, Vangeli V. Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy. Antiviral Therapy 2022;27:135965352110676. [DOI: 10.1177/13596535211067602] [Reference Citation Analysis]
|
2 |
Lv XH, Yang JL, Deng K. Letter to the Editor: Unanswered questions about hepatitis B virus infection in patients with COVID-19. Hepatology 2022;75:229. [PMID: 34387876 DOI: 10.1002/hep.32098] [Reference Citation Analysis]
|
3 |
Bekçibaşı M, Arslan E. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) /Hepatitis B virus (HBV) Co-infected Patients: A case series and review of the literature. Int J Clin Pract 2021;75:e14412. [PMID: 34051031 DOI: 10.1111/ijcp.14412] [Reference Citation Analysis]
|
4 |
Yang S, Wang S, Du M, Liu M, Liu Y, He Y. Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis. Infect Dis Ther 2022. [PMID: 35471766 DOI: 10.1007/s40121-022-00638-4] [Reference Citation Analysis]
|
5 |
Aghbash PS, Eslami N, Shirvaliloo M, Baghi HB. Viral coinfections in COVID-19. J Med Virol 2021;93:5310-22. [PMID: 34032294 DOI: 10.1002/jmv.27102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
6 |
Wang SH, Yeh SH, Chen PJ. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers (Basel) 2021;13:2454. [PMID: 34070067 DOI: 10.3390/cancers13102454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|